Accrufer patents expiration

ACCRUFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(7 years from now)

US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(11 years from now)

Accrufer is owned by Shield Tx.

Accrufer contains Ferric Maltol.

Accrufer has a total of 3 drug patents out of which 0 drug patents have expired.

Accrufer was authorised for market use on 25 July, 2019.

Accrufer is available in capsule;oral dosage forms.

Accrufer can be used as method of treating iron deficiency.

Drug patent challenges can be filed against Accrufer from 2023-07-26.

The generics of Accrufer are possible to be released after 23 October, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 2023-07-26

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency


More Information on Dosage

ACCRUFER family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic